



Universiteit  
Leiden  
The Netherlands

## **Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients**

Seyrek, N.; Hollemans, E.; Osanto, S.; Pelger, R.C.M.; Poel, H.G. van der; Bekers, E.; ... ; Leenders, G.J.L.H. van

### **Citation**

Seyrek, N., Hollemans, E., Osanto, S., Pelger, R. C. M., Poel, H. G. van der, Bekers, E., ... Leenders, G. J. L. H. van. (2021). Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients. *Histopathology*, 80(3), 558-565. doi:10.1111/his.14590




Version: Publisher's Version

License: [Creative Commons CC BY-NC-ND 4.0 license](https://creativecommons.org/licenses/by-nc-nd/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3278613>

**Note:** To cite this publication please use the final published version (if applicable).

# Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients

Neslisah Seyrek,<sup>1,2</sup>  Eva Hollemans,<sup>1</sup>  Susanne Osanto,<sup>3</sup> Rob C M Pelger,<sup>4</sup> Henk G van der Poel,<sup>5</sup> Elise Bekers,<sup>6</sup> Chris H Bangma,<sup>7</sup> John Rietbergen,<sup>8</sup> Monique J Roobol,<sup>7</sup> Ivo G Schoots<sup>2</sup> & Geert J L H van Leenders<sup>1</sup> 

<sup>1</sup>Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, <sup>2</sup>Department of Radiology, Erasmus MC Cancer Institute, Rotterdam, <sup>3</sup>Department of Medical Oncology, Leiden University Medical Centre, Leiden, <sup>4</sup>Department of Urology, Leiden University Medical Centre, Leiden, <sup>5</sup>Department of Urology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, <sup>6</sup>Department of Pathology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, <sup>7</sup>Department of Urology, Erasmus MC Cancer Institute, Rotterdam, and <sup>8</sup>Department of Urology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands

Date of submission 6 September 2021

Accepted for publication 26 October 2021

Published online Article Accepted 27 October 2021

Seyrek N, Hollemans E, Osanto S, Pelger RCM, van der Poel HG, Bekers E, Bangma CH, Rietbergen J, Roobol MJ, Schoots IG & van Leenders GJLH

(2022) *Histopathology* 80, 558–565. <https://doi.org/10.1111/his.14590>

## Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients

**Aims:** Gleason pattern 4 (GP4) percentage, invasive cribriform and/or intraductal carcinoma (IC/IDC) and the presence of tertiary Gleason pattern 5 (TP5) in radical prostatectomy (RP) specimens all aid in the risk stratification of Grade Group (GG) 2 prostate cancer patients. However, it is unclear to what extent these pathological features are mutually related and what are their individual values if they are investigated simultaneously. The aims of this study were: (i) to determine the mutual relationships of the GP4 percentage, IC/IDC and TP5 in GG2 RP specimens; and (ii) to assess their prognostic value for biochemical recurrence-free survival (BCRFS).

**Methods and results:** Of 1064 RP specimens, 472 (44.4%) showed GG2 prostate cancer. Patients with  $\geq 25\%$  GP4 more frequently had IC/IDC (67.0% versus 43.9%;  $P < 0.001$ ) and TP5 (20.6% versus 5.8%;  $P < 0.001$ ) than those with  $< 25\%$  GP4. In unadjusted

analysis, an increased GP4 percentage [hazard ratio (HR) 1.3; 95% confidence interval (CI) 1.0–1.6;  $P = 0.04$ ] and IC/IDC (log rank  $P < 0.001$ ) were associated with shorter BCRFS, whereas TP5 ( $P = 0.12$ ) and a dichotomised ( $< 25\%$ ,  $\geq 25\%$ ) GP4 percentage ( $P = 0.10$ ) were not. In multivariable analysis, IC/IDC was an independent prognostic factor (HR 1.9; 95% CI 1.2–2.9;  $P = 0.005$ ) for BCRFS, whereas a continuous or dichotomised GP4 percentage and TP5 were not independent prognostic factors.

**Conclusion:** In conclusion, a higher GP4 percentage in RP specimens was associated with more frequent IC/IDC and TP5. IC/IDC was an independent predictor for BCRFS, whereas the GP4 percentage and TP5 were not. These findings underscore the importance of routinely including the presence of IC/IDC in RP pathology reports.

**Keywords:** cribriform, Gleason score, prostate cancer, quantity, radical prostatectomy, tertiary pattern

Address for correspondence: N Seyrek, MD, Department of Radiology, Erasmus MC Cancer Institute, Na-2523, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. e-mail: n.seyrek@erasmusmc.nl

© 2021 The Authors. *Histopathology* published by John Wiley & Sons Ltd.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

## Introduction

The Gleason grading system is one of the cornerstones of prostate cancer (PCa) risk stratification and clinical decision-making. In radical prostatectomy (RP) specimens, the Gleason score/Grade Group (GG) is determined by adding the most common Gleason patterns. Patients with a biopsy Gleason score of 6 (GG1) are often eligible for active surveillance, and those with GG1 disease in RP specimens have a very low, if any, risk of developing metastasis.<sup>1,2</sup> In contrast, patients with biopsy GG3–5 PCa are considered to have aggressive disease and will generally be treated with RP, radiation therapy, and/or hormonal therapy. The clinical outcome of patients with biopsy Gleason score 3 + 4 = 7 (GG2) PCa is highly variable, with an increasing number of patients being considered to be eligible for active surveillance.<sup>3,4</sup>

GG2 PCa is pathologically a heterogeneous disease, with variable Gleason pattern 4 (GP4) percentages and different growth patterns. The risk of biochemical recurrence increases with an increasing GP4 percentage in RP specimens.<sup>5</sup> GP4 includes poorly formed, fused, cribriform and glomeruloid glandular structures. In recent years, cribriform architecture has been associated with biochemical recurrence, metastatic disease, and disease-specific mortality.<sup>1,5–9</sup> Cribriform architecture can occur as an invasive GP4 structure or as intraductal carcinoma of the prostate, in which the malignant proliferation is present within distended pre-existing glands with a basal cell layer. Because invasive cribriform and/or intraductal carcinoma (IC/IDC) is an independent predictor for an adverse clinical outcome, the International Society of Urological Pathology (ISUP) and Genitourinary Pathology Society recommend reporting its presence in biopsy and RP specimens.<sup>10,11</sup> Finally, the presence of minor/tertiary components of Gleason pattern 5 (TP5) constituting <5% of the tumour volume in GG2 RP specimens has been associated with shorter biochemical recurrence-free survival (BCRFS).<sup>12,13</sup>

The GP4 percentage, IC/IDC and TP5 aid in the risk stratification of GG2 PCa patients. Most studies, however, have analysed only one of these pathological features without adjusting for the other prognostic factors. Therefore, at present, it is not clear to what extent these pathological features are mutually related and which of them have independent prognostic value if investigated simultaneously.<sup>10</sup> The aims of our study were: (i) to determine the mutual relationships of the GP4 percentage, IC/IDC and TP5 in GG2 RP specimens; and (ii) to assess their prognostic value for BCRFS.

## Materials and methods

### PATIENT SELECTION

Patients who had undergone RP for prostatic adenocarcinoma at three medical centres in The Netherlands between 2000 and 2017 were included in this study; 854 patients were operated on at Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, 96 at Leiden University Medical Centre (LUMC), Leiden, and 137 at Antoni van Leeuwenhoek Hospital, the Netherlands Cancer Institute (NKI), Amsterdam. Whereas the operation specimens of Erasmus MC were unselected consecutive samples, those from LUMC and the NKI were selected for the presence of GG3–5 disease in the original pathology report in order to increase the number of high-grade tumours. We excluded patients who had undergone hormonal, radiation and/or viral therapy ( $n = 23$ ) before operation. RP specimens were fixed in neutral-buffered formalin, after which they were sectioned transversely and embedded in their entirety for diagnostic purposes. All slides were available for pathology review. The institutional Medical Research Ethics Committee approved this study (MEC-2018-1614).

### PATHOLOGICAL EVALUATION

All 1064 RP specimens were reviewed in joint sessions by two investigators (E.H. and G.v.L.) blinded to clinical outcome. For each specimen, the following features were recorded: Gleason score and GG according to the 2014 ISUP/2016 World Health Organisation guidelines, pT stage according to the American Joint Committee on Cancer TNM 8th edition, surgical margin status, the presence of IC/IDC, and the percentages of GP4 and TP5. Invasive cribriform and intraductal carcinoma were not distinguished and were grouped for all analyses. We defined the cribriform pattern as a contiguous epithelial proliferation: (i) in which the majority of tumour cells do not contact the surrounding stroma; (ii) with a gland-like space surrounding less than half of the sheet circumference; and (iii) with regular intercellular lumens clearly visible on haematoxylin and eosin-stained sections.<sup>14–17</sup> Specifically regarding point (ii) above, glomeruloid structures and roman bridging were not considered to indicate a cribriform pattern. In cases of multifocality, we only monitored the characteristics of the index tumour defined as the tumour with the highest grade, stage, or volume. In none of the cases was IC/IDC or TP5 absent in the index tumour but present in a non-index lesion. Tertiary patterns

occupying <5% of the tumour volume and IDC were not included in the Gleason score. The GG concordance rates at revision were 88/135 (65.2%) for RP specimens from the NKI and 39/94 (41.5%) for RP specimens from LUMC.

#### CLINICAL FOLLOW-UP

Clinical follow-up after RP consisted of 6-monthly, and later annual, monitoring of serum prostate-specific antigen (PSA) levels. Biochemical recurrence was defined as PSA levels of  $\geq 0.2$  ng/ml measured at two consecutive points in time, at least 3 months apart, with undetectable PSA levels after the operation. Postoperative lymph node and distant metastases were confirmed by biopsy, imaging, and/or multidisciplinary consensus.

#### STATISTICAL ANALYSIS

Continuous variables were analysed with the Mann–Whitney *U*-test. For comparison of categorical parameters, Pearson's chi-squared ( $\chi^2$ ) test was used, and Fisher's exact test was used in the case of small numbers ( $n \leq 20$ ). Missing PSA values ( $n = 27$ ) were imputed by use of the median PSA value. BCRFS and metastasis-free survival were analysed with the Cox proportional hazards model and visualised by the use of Kaplan–Meier curves. Statistical analyses were performed with SPSS version 25 (IBM, Chicago, IL, USA). Results were considered significant when the two-sided *P*-value was  $< 0.05$ .

## Results

#### PATIENT CHARACTERISTICS

Of 1064 RP specimens, 472 (44.4%) showed GG2 PCa. The median age at time of operation was 63.8 years [interquartile range (IQR) 60.0–68.0 years], and the median serum PSA level was 11.0 ng/ml (IQR 6.0–12.9 ng/ml). The pathological tumour stages were T2 in 268 (56.8%) patients, T3a in 169 (35.8%) patients, and T3b in 35 (7.4%) patients. Positive surgical margins were present in 156 (33.1%) cases. Of 249 (52.8%) patients who had undergone pelvic lymph node dissection, 13 (5.2%) had lymph node metastasis. The median GP4 percentage was 20.0% (IQR 10.0–30.0%); 278 (58.9%) patients had GP4 percentages in the range 5–24%, and 194 (41.1%) had GP4 percentages in the range 25–49%. IC/IDC was observed in 252 (53.4%) patients, and TP5 in 56 (11.9%) patients. The

median clinical follow-up was 38 months (IQR 10.4–77.5 months). In total 107 (22.7%) GG2 patients developed postoperative biochemical recurrence after a median of 24 months, and 18 (3.8%) developed postoperative metastasis.

#### GP4 PERCENTAGES

The clinicopathological features of GG2 patients stratified for 5–4% (278/472; 58.9%) and 25–49% (194/472; 41.1%) are shown in Table 1. TP5 was observed significantly ( $P < 0.001$ ) more often in patients with  $\geq 25\%$  GP4 (40/194; 20.6%) than in those with  $< 25\%$  GP4 (16/278; 5.8%). Also, IC/IDC was observed significantly more often in patients with  $\geq 25\%$  GP4 (130/194; 67.0%) than in those with  $< 25\%$  GP4 (122/278; 43.9%;  $P < 0.001$ ). Patients with  $\geq 25\%$  GP4 more frequently had extraprostatic extension (pT3; 95/194; 49.0%) and were older than those with  $< 25\%$  GP4 (109/278; 39.2%;  $P = 0.01$ ). Serum PSA levels, pelvic lymph node metastasis and

**Table 1.** Clinicopathological characteristics of Grade Group 2 patients ( $n = 472$ ) stratified for Gleason pattern 4 (GP4) percentages of 5–24% and 25–49%

|   | <25% GP4<br><i>N</i> = 278 | $\geq 25\%$ GP4<br><i>N</i> = 194 | <i>P</i> -value |
|---|----------------------------|-----------------------------------|-----------------|
| Age (years),<br>median (IQR)              | 64.0 (59.1–67.8)           | 64.8 (61.5–68.7)                  | 0.03            |
| PSA (ng/ml),<br>median (IQR)              | 10.9 (6.0–13.0)            | 8.3 (6.0–12.4)                    | 0.72            |
| pT stage, <i>n</i> (%)                    |                            |                                   | 0.01            |
| pT2                                       | 169 (60.8)                 | 99 (51.0)                         |                 |
| pT3a                                      | 96 (34.5)                  | 73 (37.6)                         |                 |
| pT3b                                      | 13 (4.7)                   | 22 (11.4)                         |                 |
| Positive surgical<br>margin, <i>n</i> (%) | 93 (33.5)                  | 63 (32.5)                         | 0.82            |
| pN stage <i>n</i> (%)                     |                            |                                   | 0.29            |
| pN0                                       | 141 (50.7)                 | 108 (55.7)                        |                 |
| pN1                                       | 6 (2.2)                    | 7 (3.6)                           |                 |
| pNx                                       | 131 (47.1)                 | 79 (30.7)                         |                 |
| IC/IDC                                    | 122 (43.9)                 | 130 (67.0)                        | <0.001          |
| TP5                                       | 16 (5.8)                   | 40 (20.6)                         | <0.001          |

IC/IDC, invasive cribriform and/or intraductal carcinoma; IQR, interquartile range; PSA, prostate-specific antigen; TP5, tertiary Gleason pattern 5.

surgical margin positivity were not significantly different between the groups. Postoperative biochemical recurrence occurred in 56 of 278 (20.1%) men with <25% GP4 and in 51 of 194 (26.3%) patients with  $\geq 25\%$  GP4. Univariate Cox regression analysis revealed that the GP4 percentage GP4 as a continuous variable had prognostic value for BCRFS [hazard ratio (HR) 1.3; 95% confidence interval (CI) 1.0–1.6;  $P = 0.04$ ]. BCRFS was not statistically different when the GP4 percentage was dichotomised as <25% and  $\geq 25\%$  (log-rank  $P = 0.10$ ; Figure 1A). Thirteen (6.7%) patients with  $\geq 25\%$  GP4 developed postoperative metastasis, as compared with five (1.8%) of those with <25% GP4 (log rank;  $P = 0.003$ ).

#### CRIBRIFORM ARCHITECTURE

The number of GG2 patients with IC/IDC was 252 (53.4%) (Table 2). The GP4 percentages were 25.0% (IQR 20.0–33.7%) in patients with IC/IDC and 15.0% (IQR 10.0–30.0%) in those without ( $P < 0.001$ ). TP5 was observed in 34 (13.5%) IC/IDC-positive and 22 (10.0%) IC/IDC-negative samples ( $P = 0.24$ ). The median PSA level of the patients with IC/IDC was 12.1 ng/ml (IQR 6.3–13.5 ng/ml), which was significantly higher than that of those without IC/IDC (8.0 ng/ml, IQR 5.6–11.1 ng/ml;  $P = 0.02$ ). Patients with IC/IDC more frequently had extraprostatic extension (126/252; 50.0% versus 78/220; 35.4%;  $P < 0.001$ ), and positive surgical margins (97/252; 38.5% versus 59/220; 26.8%;  $P = 0.007$ ) than those without. All 13 patients with pelvic lymph node metastasis had IC/IDC within their RP specimen; no metastases occurred in patients without IC/IDC ( $P < 0.001$ ). BCRFS in patients with IC/IDC (73/252; 29.0%) was shorter (log rank  $P < 0.001$ ) than in those without (34/220; 15.5%) (Figure 1B). Eighteen


(7.1%) patients with IC/IDC developed postoperative metastasis, whereas none of 220 patients without IC/IDC did so (log rank  $P < 0.001$ ).

#### TP5

The median GP4 percentage of patients with TP5 (30.0%, IQR 20.0–40.0%) was significantly ( $P < 0.001$ ) higher than that of those without TP5 (20.0%, IQR 10.0–30.0%). PSA levels (9.2 ng/ml, IQR 7.3–16.4 ng/ml) were also higher ( $P = 0.03$ ) when TP5 was present than when it was not (8.3 ng/ml, IQR 5.9–12.1 ng/ml). IC/IDC was observed in 34 of 56 (60.7%) patients with TP5 and in 218 of 416 (52.4%) of those without ( $P = 0.24$ ). Age, pT stage, surgical margin status and pelvic lymph node metastasis were not significantly different between the two groups (Table 3). Sixteen of 56 (28.6%) patients with TP5 developed biochemical recurrence as compared with 91 of 416 (21.9%) of those without; BCRFS was not statistically significant in this cohort (Figure 1C; log rank  $P = 0.12$ ). Four of 56 (7.1%) patients with TP5 developed postoperative metastasis as compared with 14 of 416 (3.4%) without (log rank  $P = 0.04$ ).

#### MULTIVARIABLE ANALYSIS

In Cox regression analysis adjusted for routine clinicopathological parameters, i.e. the GP4 percentage, IC/IDC, and TP5, the presence of IC/IDC was an independent prognostic factor (HR 1.7; 95% CI 1.1–2.6;  $P = 0.02$ ) for BCRFS (Table 4). The GP4 percentage, included either as a continuous parameter (HR 1.0; 95% CI 0.8–1.3;  $P = 0.64$ ) or a categorical parameter (5–24%; 25–49%) (HR 1.1; 95% CI 0.7–1.6;  $P = 0.71$ ), and TP5 (HR 0.7; 95% CI 0.4–1.3;



**Figure 1.** Biochemical recurrence-free survival in patients with Grade Group 2 prostate cancer, stratified for: (A) Gleason pattern 4 (log-rank  $P = 0.10$ ); (B) invasive cribriform and/or intraductal carcinoma (log-rank  $P < 0.001$ ); and (C) tertiary Gleason pattern 5 (log-rank  $P = 0.12$ ).

**Table 2.** Clinicopathological characteristics of Grade Group 2 patients ( $N = 472$ ) stratified for the presence of invasive cribriform and/or intraductal carcinoma (IC/IDC)

|                                   | IC/IDC-negative<br>$N = 220$ | IC/IDC-positive<br>$N = 252$ | $P$ -value |
|-----------------------------------|------------------------------|------------------------------|------------|
| Age (years), median (IQR)         | 63.1 (59.4–68.1)             | 64.7 (60.3–67.9)             | 0.22       |
| PSA (ng/ml), median (IQR)         | 8.0 (5.6–11.1)               | 12.1 (6.3–13.5)              | 0.02       |
| pT stage, $n$ (%)                 |                              |                              | <0.001     |
| pT2                               | 142 (64.5)                   | 126 (50.0)                   |            |
| pT3a                              | 72 (32.7)                    | 97 (38.5)                    |            |
| pT3b                              | 6 (2.7)                      | 29 (11.5)                    |            |
| Positive surgical margin, $n$ (%) | 59 (26.8)                    | 97 (38.5)                    | 0.007      |
| pN stage, $n$ (%)                 |                              |                              | <0.001     |
| pN0                               | 102 (46.4)                   | 147 (58.3)                   |            |
| pN1                               | 0 (0.0)                      | 13 (100.0)                   |            |
| pNx                               | 118 (53.6)                   | 92 (36.5)                    |            |
| % GP4 (continuous), median (IQR)  | 15.0 (10.0–30.0)             | 25.0 (20.0–33.7)             | <0.001     |
| % GP4 (categorical), $n$ (%)      |                              |                              | <0.001     |
| 5–24                              | 156 (70.9)                   | 122 (48.4)                   |            |
| 25–49                             | 64 (29.1)                    | 130 (51.6)                   |            |
| TP5, $n$ (%)                      | 22 (10.0)                    | 34 (13.5)                    | 0.24       |

GP4, Gleason pattern 4; IQR, interquartile range; PSA, prostate-specific antigen; TP5, tertiary Gleason pattern 5.

$P = 0.33$ ) did not have prognostic value in multivariable analysis (Table 4). This outcome was unchanged when PSA was excluded from multivariable analysis. In total, 18 of 472 (3.8%) patients developed postoperative metastasis after a median of 58 months. All of these 18 patients had IC/IDC in RP specimens, 13 of 18 (72.2%) had  $\geq 25\%$  GP4, and four of 18 (22.2%) had TP5. The number of metastatic events was too small for further analysis.

## Discussion

The GP4 percentage, IC/IDC and the presence of TP5 have added value in the risk stratification of GG2 PCA

**Table 3.** Clinicopathological characteristics of Grade Group 2 patients ( $N = 472$ ) stratified for tertiary Gleason pattern 5 (TP5)

|                                   | TP5 absent<br>$N = 416$ | TP5 present<br>$N = 56$ | $P$ -value |
|-----------------------------------|-------------------------|-------------------------|------------|
| Age (years), median (IQR)         | 64.6 (56.7–68.1)        | 64.4 (60.6–67.9)        | 0.63       |
| PSA (ng/ml), median (IQR)         | 8.3 (5.9–12.1)          | 9.2 (7.3–16.4)          | 0.03       |
| pT stage, $n$ (%)                 |                         |                         | 0.06       |
| pT2                               | 243 (58.4)              | 25 (44.6)               |            |
| pT3a                              | 145 (34.9)              | 24 (42.9)               |            |
| pT3b                              | 28 (6.7)                | 7 (12.5)                |            |
| Positive surgical margin, $n$ (%) | 139 (33.2)              | 17 (30.4)               | 0.76       |
| pN, $n$ (%)                       |                         |                         | 0.10       |
| pN0                               | 220 (52.9)              | 29 (51.8)               |            |
| pN1                               | 9 (2.2)                 | 4 (7.1)                 |            |
| pNx                               | 187 (45.0)              | 23 (41.1)               |            |
| % GP4 (continuous), median (IQR)  | 20.0 (10.0–30.0)        | 30.0 (20.0–40.0)        | <0.001     |
| % GP4 (categorical), median (IQR) |                         |                         | <0.001     |
| 5–24                              | 262 (63.0)              | 16 (28.6)               |            |
| 25–49                             | 154 (37.0)              | 40 (71.4)               |            |
| IC/IDC                            | 218 (52.4)              | 34 (60.7)               | 0.24       |

GP4, Gleason pattern 4; IC/IDC, invasive cribriform and/or intraductal carcinoma; IQR, interquartile range; PSA, prostate-specific antigen.

patients. As these pathological features have mostly been assessed individually, it is not yet clear to what extent they are mutually related and what their impact is if the other features are taken into account. In this study, we demonstrate that the GP4 percentage, the presence of IC/IDC and TP5 are mutually related in GG2 RP specimens. In multivariable analysis, IC/IDC was an independent prognostic parameter for BCRFS, whereas the GP4 percentage and TP5 were not. These findings suggest that the clinical value of the GP4 percentage and TP5 can, at least in part, be attributed to their association with IC/IDC, and underscore the importance of routinely reporting the presence of IC/IDC.

**Table 4.** Cox regression analysis of biochemical recurrence-free survival (BCRFS) in Grade Group 2 prostate cancer patients

|                          | Univariate analysis |          |         | Multivariable analysis |          |         |
|--------------------------|---------------------|----------|---------|------------------------|----------|---------|
|                          | HR                  | 95% CI   | P-value | HR                     | 95% CI   | P-value |
| PSA*                     | 1.6                 | 1.3–1.9  | <0.001  | 1.2                    | 1.0–1.5  | 0.03    |
| pT stage                 |                     |          |         |                        |          |         |
| pT2                      | Ref.                |          |         | Ref.                   |          |         |
| pT3a                     | 1.7                 | 1.1–2.7  | 0.008   | 1.4                    | 0.9–2.1  | 0.17    |
| pT3b                     | 4.9                 | 2.8–8.5  | <0.001  | 2.0                    | 1.0–3.8  | 0.04    |
| Positive surgical margin | 2.5                 | 1.7–3.7  | <0.001  | 2.0                    | 1.3–3.0  | 0.001   |
| pN stage                 |                     |          |         |                        |          |         |
| pN0                      | Ref.                |          |         | Ref.                   |          |         |
| pN1                      | 12.0                | 5.9–24.2 | <0.001  | 6.7                    | 2.9–15.1 | <0.001  |
| pNx                      | 0.5                 | 0.3–0.8  | 0.004   | 0.7                    | 0.4–1.1  | 0.09    |
| % GP4 (continuous)*      | 1.3                 | 1.0–1.6  | 0.04    | 1.0                    | 0.8–1.3  | 0.64    |
| IC/IDC                   | 2.4                 | 1.6–3.6  | <0.001  | 1.7                    | 1.1–2.6  | 0.02    |
| TP5                      | 1.5                 | 0.9–2.6  | 0.12    | 0.7                    | 0.4–1.3  | 0.33    |

CI, confidence interval; GP4, Gleason pattern 4; HR, hazard ratio; PSA, prostate-specific antigen; TP5, tertiary Gleason pattern 5.

\*2 log.

Although several studies have shown prognostic value for the GP4 percentage, IC/IDC, and TP5, only a few have analysed these parameters simultaneously. For instance, Choy *et al.* showed that both cribriform architecture and a higher GP4 percentage in RP specimens were independently associated with lower 5-year BCRFS in 350 combined GG2 and GG3 patients.<sup>5</sup> Although their finding regarding cribriform carcinoma is in line with our study, the independent value of the GP4 percentage is not. A possible explanation is that we included the GP4 percentage as a continuous variable, whereas Choy *et al.* categorised it as 1–20%, 21–50%, 51–70%, and >70%. Dichotomisation of continuous variables may, however, lead to bias. Furthermore, Choy *et al.* included patients with 1–5% GP4, whereas we excluded those as being GG1 with tertiary GP4. As patients with 1–5% GP4 had the longest BCRFS in their study, the inclusion of this subgroup might have affected the outcome of the multivariable analysis. Kweldam *et al.* found that IC/IDC was more common in GG2 biopsies with a higher GP4 percentage.<sup>18</sup> In multivariable analysis of postoperative BCRFS, IC/IDC was an independent factor, whereas GP4 percentage was not, which is in line with the current RP study. Finally, in an RP cohort of 8057 GG2 patients, Sauter *et al.* showed that both GP4

percentage and the presence of TP5 had additional value in predicting BCRFS.<sup>12</sup> The frequency of TP5 in the study of Sauter *et al.* (742/8057; 9.2%) was comparable to ours (56/472; 11.9%). In our study, patients with TP5 had lower BCRFS rates than those without, but this difference was not statistically significant. A possible explanation might be our relatively small study population, which limited powerful statistical analysis of subtle differences. As Sauter *et al.* did not include IC/IDC, the impact of this parameter in their large cohort is unknown.

Our findings corroborate the adverse impact of the presence of IC/IDC in PCa patients. An increased GP4 percentage and the presence of TP5 have also been identified as pathological parameters associated with an adverse outcome. In our study, we showed that these three parameters are related. Among GG2 patients with  $\geq 25\%$  GP4, 67% had IC/IDC and 21% had TP5, whereas these figures were 44% and 6%, respectively, in patients with  $< 25\%$  GP4. Although TP5 was observed slightly more often in patients with IC/IDC than in those without, this difference was not statistically significant, which may be due to the relatively small sample size. Validation of these mutual relationships and adjusted analysis in future studies will be important to confirm the current data, and to

obtain comprehensive insights into the independent clinical impacts of these pathological features.

Interobserver variability is one of the most important caveats regarding PCa grading. Two studies showed that reproducibility of cribriform architecture is substantially better than that of other growth patterns.<sup>19,20</sup> In an interobserver study of 80 RP slides, the reproducibility of assigning TP5 was lower than those of IC/IDC and the GP4 percentage.<sup>21</sup> As far as we know, no specific interobserver studies have yet been performed on tertiary patterns. We hypothesise that the reproducibility of assigning TP5 is low because it can be overlooked or interpreted as poorly formed GP4. Also, estimation of minor pattern volumes might be troublesome. In a Gleason score 3 + 4 = 7 tumour, estimation of a minor TP5 component as 6% would imply upgrading to a Gleason score of 3 + 5 = 8, whereas it would be regarded as a Gleason score 3 + 4 = 7 tumour with TP5 if the minor component was assessed as 4%.<sup>10,22</sup> Also, any IC/IDC presence, even if its volume is limited, is associated with an adverse outcome, facilitating its use in clinical practice.<sup>23,24</sup>

The presence of a cribriform pattern is most relevant in patients with intermediate-risk PCa on biopsy, in whom it can directly affect eligibility for active surveillance. Although a cribriform pattern does not generally have an influence on postoperative therapy, the very low risk of metastasis in GG2 patients without a cribriform pattern might facilitate the communication of RP outcome and reduce the intensity of long-term follow-up.

To our knowledge, this is the first study addressing the mutual relationships of the GP4 percentage, IC/IDC and TP5 in GG2 RP specimens. Strengths of this study are the inclusion of a relatively large RP cohort and detailed monitoring of pathological parameters. The retrospective design and relatively short follow-up period are general weaknesses of our study. Although all parameters were individually associated with metastasis-free survival, multivariable analysis was not possible, owing to the low number of events. In that sense, it is of interest to note that GG2 patients without IC/IDC in RP specimens had comparable excellent metastasis-free survival to that of GG1 patients in the same cohort.<sup>25</sup>

In conclusion, the GP4 percentage, the presence of IC/IDC and TP5 are mutually related in GG2 RP specimens. Although both the GP4 percentage and IC/IDC were prognostic for BCRFS in univariate analysis, IC/IDC was the only independent factor that was prognostic for BCRFS in adjusted analysis; the GP4 percentage and TP5 were not. This outcome underscores the importance of explicitly including the

presence or absence of a cribriform pattern in RP pathology reports.

## Acknowledgements

This study was supported by a generous grant from the Jaap Schouten Foundation.

## Conflicts of interest

The authors declare no conflicts of interest.

## Author contributions

N. Seyrek and E. Hollemans performed the research. N. Seyrek analysed the data and wrote the manuscript. S. Osanto, R. C. M. Pelger, H. G. van der Poel, E. Bekers, C. H. Bangma, J. Rietbergen and M. J. Roobol included patients with clinical follow-up. I. G. Schoots and G. J. L. H. van Leenders supervised the analysis and manuscript drafting. G. J. L. H. van Leenders designed the study.

## References

1. Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH, van Leenders GJ. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in gleason score 7 prostate cancer. *Mod. Pathol.* 2015; **28**: 457–464.
2. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with gleason score (gs)  $\leq 6$  have the potential to metastasize to lymph nodes? *Am. J. Surg. Pathol.* 2012; **36**: 1346–1352.
3. Amin MB, Lin DW, Gore JL *et al.* The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the college of american pathologists, international society of urological pathology, association of directors of anatomic and surgical pathology, the new zealand society of pathologists, and the prostate cancer foundation. *Arch. Pathol. Lab. Med.* 2014; **138**: 1387–1405.
4. Lam TBL, MacLennan S, Willemse PM *et al.* Eau-eanm-estrosur-siog prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (detective study). *Eur. Urol.* 2019; **76**: 790–813.
5. Choy B, Pearce SM, Anderson BB *et al.* Prognostic significance of percentage and architectural types of contemporary gleason pattern 4 prostate cancer in radical prostatectomy. *Am. J. Surg. Pathol.* 2016; **40**: 1400–1406.
6. Flood TA, Schieda N, Sim J *et al.* Evaluation of tumor morphologies and association with biochemical recurrence after radical prostatectomy in grade group 5 prostate cancer. *Virchows Arch.* 2018; **472**: 205–212.



7. Harding-Jackson N, Kryvenko ON, Whittington EE *et al.* Outcome of gleason 3 + 5 = 8 prostate cancer diagnosed on needle biopsy: prognostic comparison with gleason 4 + 4 = 8. *J. Urol.* 2016; **196**: 1076–1081.
8. Hollemans E, Verhoef EI, Bangma CH *et al.* Large cribriform growth pattern identifies isup grade 2 prostate cancer at high risk for recurrence and metastasis. *Mod. Pathol.* 2019; **32**: 139–146.
9. Downes MR, Xu B, van der Kwast TH. Gleason grade patterns in nodal metastasis and corresponding prostatectomy specimens: impact on patient outcome. *Histopathology* 2019; **75**: 715–722.
10. van Leenders GJLH, van der Kwast TH, Grignon DJ *et al.* The 2019 international society of urological pathology (isup) consensus conference on grading of prostatic carcinoma. *Am. J. Surg. Pathol.* 2020; **44**: e87–e99.
11. Epstein JI, Amin MB, Fine SW *et al.* The 2019 genitourinary pathology society (gup) white paper on contemporary grading of prostate cancer. *Arch. Pathol. Lab. Med.* 2021; **145**: 461–493.
12. Sauter G, Steurer S, Clauditz TS *et al.* Clinical utility of quantitative gleason grading in prostate biopsies and prostatectomy specimens. *Eur. Urol.* 2016; **69**: 592–598.
13. Baras AS, Nelson JB, Han M, Parwani AV, Epstein JI. The effect of limited (tertiary) gleason pattern 5 on the new prostate cancer grade groups. *Hum. Pathol.* 2017; **63**: 27–32.
14. van Leenders G, Verhoef EI, Hollemans E. Prostate cancer growth patterns beyond the gleason score: entering a new era of comprehensive tumour grading. *Histopathology* 2020; **77**: 850–861.
15. van Leenders GJLH, Kweldam CF, Hollemans E *et al.* Improved prostate cancer biopsy grading by incorporation of invasive cribriform and intraductal carcinoma in the 2014 grade groups. *Eur. Urol.* 2020; **77**: 191–198.
16. van der Kwast TH, van Leenders GJ, Berney DM *et al.* Isup consensus definition of cribriform pattern prostate cancer. *Am. J. Surg. Pathol.* 2021; **45**: 1118–1126.
17. Shah RB, Cai Q, Aron M *et al.* Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. *Am. J. Cancer Res.* 2021; **11**: 3990–4001.
18. Kweldam CF, Kümmerlin IP, Nieboer D *et al.* Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of gleason score 3+4=7 prostate cancer. *Mod. Pathol.* 2017; **30**: 1126–1132.
19. Egevad L, Ahmad AS, Algaba F *et al.* Standardization of gleason grading among 337 european pathologists. *Histopathology* 2013; **62**: 247–256.
20. Kweldam CF, Nieboer D, Algaba F *et al.* Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. *Histopathology* 2016; **69**: 441–449.
21. van der Slot MA, Hollemans E, den Bakker MA *et al.* Interobserver variability of cribriform architecture and percent gleason pattern 4 in prostate cancer: relation to clinical outcome. *Virchows Arch.* 2021; **478**: 249–256.
22. Holger Moch PAH, Ulbright TM, Reuter VE. *Who classification of tumours of the urinary system and male genital organs.* 4th ed. Lyon, France: Agency for Research on Cancer (IARC), 2016; 135–167.
23. Kweldam CF, Kümmerlin IP, Nieboer D *et al.* Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. *Mod. Pathol.* 2016; **29**: 630–636.
24. Trudel D, Downes MR, Sykes J, Kron KJ, Trachtenberg J, van der Kwast TH. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. *Eur. J. Cancer* 2014; **50**: 1610–1616.
25. Hollemans E, Verhoef EI, Bangma CH *et al.* Clinical outcome comparison of grade group 1 and grade group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy. *Histopathology* 2020; **76**: 755–762.